Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 15c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.44 +3.42%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.03, $0.15 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $44.3 million versus the consensus estimate of $43.45 million.
Sees combined net product sales from both HETLIOZ® and Fanapt® $180 to $200 million
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- 374Water Inc (SCWO) Misses Q2 EPS by 15c
- Iridex Corp (IRIX) Misses Q2 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
